Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

INTRODUCTION: AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmacokinetic (PK) profile, maximum tolerated dose (MTD) and efficacy of AZD4877...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Esaki, Taito, Seto, Takashi, Ariyama, Hiroshi, Arita, Shuji, Fujimoto, Chinatsu, Tsukasa, Koichiro, Kometani, Takuro, Nosaki, Kaname, Hirai, Fumihiko, Yagawa, Katsuro
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Inc 2011
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3130141/
https://ncbi.nlm.nih.gov/pubmed/21765863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1753-5174.2011.00034.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars